Your browser doesn't support javascript.
loading
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Potkin, Steven G; Loze, Jean-Yves; Forray, Carlos; Baker, Ross A; Sapin, Christophe; Peters-Strickland, Timothy; Beillat, Maud; Nylander, Anna-Greta; Hertel, Peter; Nitschky Schmidt, Simon; Eramo, Anna; Hansen, Karina; Naber, Dieter.
Afiliação
  • Potkin SG; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Loze JY; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Forray C; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Baker RA; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Sapin C; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Peters-Strickland T; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Beillat M; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Nylander AG; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Hertel P; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Nitschky Schmidt S; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Eramo A; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Hansen K; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
  • Naber D; University of California, Irvine, CA; Otsuka Pharmaceutical Europe, Wexham, UK; Lundbeck LLC, Paramus, NJ; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ; Lundbeck SAS, Issy-les-Moulineaux, France; H. Lundbeck A/S, Valby, Denmark; Lundbeck LLC, Deerfield, IL; Universi
Int J Neuropsychopharmacol ; 20(1): 40-49, 2017 01 01.
Article em En | MEDLINE | ID: mdl-27927736
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Palmitato de Paliperidona / Aripiprazol Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Revista: Int J Neuropsychopharmacol Assunto da revista: NEUROLOGIA / PSICOFARMACOLOGIA Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Palmitato de Paliperidona / Aripiprazol Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Revista: Int J Neuropsychopharmacol Assunto da revista: NEUROLOGIA / PSICOFARMACOLOGIA Ano de publicação: 2017 Tipo de documento: Article